<DOC>
	<DOCNO>NCT00111163</DOCNO>
	<brief_summary>The purpose study see whether antimalarial drug administer time routine infant vaccination prevents malaria anemia first year life .</brief_summary>
	<brief_title>Intermittent Preventive Treatment With Antimalarials Kenyan Infants</brief_title>
	<detailed_description>Approximately three quarter preschool child eastern Africa suffer anemia , define hemoglobin ( Hb ) concentration 11 g/dL . For child &lt; 5 year age , overall incidence severe malarial anemia ( Hb &lt; 5 g/dl ) estimate 15-60 case per 1,000 child per year . Other study confirm burden malaria-related anemia fall primarily infant young child . In 2000 , Schellenberg colleague , work area Tanzania low moderate level Plasmodium falciparum transmission low level sulfadoxine-pyrimethamine ( SP ) resistance , demonstrate link intermittent prophylaxis routine immunization visit national Expanded Program Immunization ( EPI ) , SP could administer child 2,3 , 9 month age , result 59 % reduction rate clinical malaria 50 % reduction rate severe anemia ( Hb &lt; 8 g/dl ) compare receive placebo . This randomized , double blind , placebo-controlled trial conduct estimate efficacy Intermittent Preventive Treatment Infants ( IPTi ) SP + three dos artesunate ( AS ) ( SP/AS3 ) give combination iron supplementation 2-6 month age routine EPI visit prevention clinical malaria , moderate anemia , severe anemia first 18 month life area intense malaria transmission near universal ownership insecticide treat net ( ITNs ) . The primary objective compare efficacy iron supplementation IPTi one 3 antimalarial regimen ( SP/AS3 , chlorproguanil-dapsone ( Lapdap ) , AQ/AS3 ) give routine EPI visit iron supplementation alone ( + placebo ) prevention clinical malaria first year life . Specific secondary objective : 1 ) Compare efficacy iron supplementation plus IPTi one 3 antimalarial regimen ( SP/AS3 , Lapdap [ chlorproguanil-dapsone ] , AQ/AS3 ) give routine EPI visit iron supplementation alone ( + placebo ) prevention moderate severe anemia first year life ; 2 ) Assess impact IPTi aforementioned regimen serologic response EPI vaccine ( Polio , Diphtheria , Tetanus , Pertussis , Hepatitis B , Hemophilus Influenzae type B , Measles ; 3 ) Assess impact IPTi aforementioned regimen ( particularly SP/AS3 ) nasal carriage rate Haemophilus influenza type b ; 4 ) Compare efficacy iron supplementation IPTi one 3 antimalarial regimen ( SP/AS3 , Lapdap [ chlorproguanil-dapsone ] , AQ/AS3 ) give routine EPI visit iron supplementation alone ( + placebo ) prevention all-cause hospitalization first year life . This trial generate important public health information efficacy IPTi prevent anemia clinical malaria among infant area intense malaria transmission ongoing prevention effort use insecticide treat net . This trial contribute towards understand IPTi 's mechanism action ( i.e . intermittent clearance parasite vs. chemoprophylactic effect afford use antimalarial long half-life ) . The information gain useful determine safety IPTi , decide sort antimalarial appropriate IPTi , ultimately help direct child survival malaria control policy African country . If alternative drug regime SP prove effective , information valuable policymakers level P. falciparum resistance SP rise increase usage east Africa .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Presenting Pentavalent 1 immunization Age 5 week 16 week Parent guardian currently resident study catchment area Parent guardian give permission child participate Known allergy study drug Current Cotrimoxazole prophylaxis Concomitant disease require hospitalization transfusion Plans away study area 6 month next year</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>malaria</keyword>
	<keyword>anemia</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>infant</keyword>
	<keyword>prevention</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>antimalarial</keyword>
</DOC>